APPENDICURE

Signet ring appendix cancer research has reached an honest turning point. The first two posts in this series covered what the published evidence says about treatment, and what the molecular biology has started to tell us. This one is about what we still do not know, why that gap exists, and what you can actually do about it.

If you are a signet ring patient or caregiver, you have probably had at least one conversation that ended with some version of this sentence. Your panel does not show anything targetable. There is no clear driver. We are going to try this and see what happens.

That experience is not a personal failure of your care team. It reflects something deeper about how cancer research has traditionally approached disease, and about why signet ring appendix cancer keeps pushing back on the old model. A research framework published in 2026 by a team at Mayo Clinic gives a name to the problem and offers a different way of looking at it. It is not a treatment and it is not standard of care, but it captures something many patients in this community have already felt without having the words for it.

A quick note on terminology. In the medical literature, this disease is often described as signet ring cell appendiceal adenocarcinoma or appendiceal adenocarcinoma with signet ring cell features. This series uses the shorter form for accessibility, but the formal terms are useful when searching the published literature.

Why Signet Ring Appendix Cancer Research Has Been So Hard

For most of the modern era of oncology, research has operated on a relatively straightforward premise: find the mutation driving tumor growth, design a therapy to target it, and treat the cancer. For some diseases, that approach has been genuinely transformative. For signet ring appendix cancer, it has been incomplete in ways the patients living with this diagnosis feel every day.

Two patients walk into a clinic with the same pathology, the same stage, and similar mutation profiles. One stays stable for years while the other recurs within months. The mutations did not change, but the outcomes did. That unpredictability is the signal, and it tells us the system driving signet ring cancer is more complicated than the testing we currently have can capture.

Standard genomic testing is designed to find what is visibly wrong. It looks at the mutations that show up in tumor cells, the genes that are expressed at unusually high or low levels, the epigenetic markings on DNA that turn genes on or off. These are real and important pieces of information. They are also, by themselves, an incomplete description of what is actually happening in a cancer cell.

To understand why researchers think important pieces of the puzzle may still be missing, it helps to look at a new framework that attempts to explain what traditional testing cannot.

A New Framework for Thinking About Disease

In early 2026, researchers at Mayo Clinic published a paper proposing a different way of modeling complex diseases. They call it the Mini-Galaxy Model. The full citation is at the bottom of this post for anyone who wants to read it directly.

The argument is straightforward. Disease does not usually emerge from one broken gene. It emerges from the combined behavior of many layers of gene activity acting together, some of which we can measure directly and some of which we cannot. Until research can account for both, the picture of any given patient’s disease is going to stay incomplete.

A Cell as a Mini-Galaxy

The framework gets its name from an analogy worth understanding. A galaxy has visible components, the stars and planets you can observe directly. It also has hidden components, black holes and dark matter, that exert enormous gravitational influence over everything around them even though they cannot be seen. The visible and the hidden together determine how the galaxy behaves.

The Mayo Clinic researchers argue that a living cell works the same way. Some gene properties are what they call salient. These are the things current testing measures: mutations, changes in gene expression, epigenetic modifications. These are the stars and planets. Other gene properties are latent, meaning they cannot be measured directly but have to be inferred through computational analysis. These are the dark matter.

Latent properties include things like how information flows through the network of protein interactions inside a cell, which gene pairs act as molecular switches that flip when a disease state changes, and which gene relationships stay stable across many patients despite individual genetic differences. The researchers also describe a category called dark gene associations, which are connections between genes that drive disease even when neither gene shows up as mutated or differentially expressed. The authors cite prior work suggesting that roughly three percent of cancer-relevant genes may fall into this category, meaning they could be functionally important despite not being identified through conventional mutation or differential-expression analyses. In a cancer where mutations have been telling an incomplete story for years, that three percent of the genome operating below the radar matters.

Why This Matters for Signet Ring Appendix Cancer Patients

Signet ring appendix cancer is one of the strongest cases for needing a different framework. Outcomes vary widely even among patients with similar pathology, similar staging, and similar treatment plans. The published evidence on signet ring percentage and lymph node status, which Part 2 of this series walked through in detail, accounts for some of that variability but not all of it. There are signet ring patients whose comprehensive genomic panels come back with nothing actionable, and there are signet ring patients whose tumors progress in ways their mutation profile would not have predicted.

If the Mini-Galaxy Model’s central hypothesis proves correct, and if broader systems biology research continues to support similar conclusions, then part of the explanation for that variability may live in biological layers current testing does not routinely reach. It may be in the network of gene interactions surrounding a mutation. It may be in the peritoneal tumor environment. It may be in patterns of gene behavior that no commercial panel is currently designed to look for.

This is not a reason to dismiss the genomic testing you have already had. Mutation profiling matters. MSI status matters, especially for signet ring patients. The point is that mutation profiling is the beginning of the picture, not the end. The research that fills in the rest is starting to take shape, and there are concrete ways for signet ring patients to be part of it.

What You Can Do Now to Be Part of Signet Ring Appendix Cancer Research

Signet ring appendix cancer research depends on tissue, data, and patients willing to participate. Without those three things in adequate volume, the field cannot move. There are five practical steps that genuinely help, and they are all things a signet ring patient or caregiver can act on without waiting for permission from the medical system.

Ask about tissue banking

Every signet ring resection or biopsy produces tissue. Most of that tissue is examined by pathology, embedded in paraffin blocks, and stored. Some of it can also be banked for research, which means it becomes available to investigators working on rare cancers like this one. If your tumor has been surgically resected and the tissue is still available, ask whether it can be banked at a center that runs an appendix or peritoneal surface malignancy research program. The Appendicure specialist directory includes centers with active tissue banks.

Ask about trials that go beyond standard mutation panels

Standard genomic testing looks at one layer of biology. A growing number of trials are starting to look at more than one layer, or to approach drug selection differently than relying on mutations alone. Multi-omics studies add things like transcriptomics, which measures gene activity, and proteomics, which measures the proteins those genes produce. Functional precision oncology takes a different angle, using laboratory measurements of how a patient’s own cancer cells actually behave to predict which treatment will work for that patient. The trial led by Dr. Kiran Turaga at Yale, registered as NCT07291180, is one example. Turaga’s team uses a technology that effectively weighs individual cancer cells to predict which intraperitoneal chemotherapy will work best for a specific patient with peritoneal disease. Ask your oncologist whether any trials of this kind, multi-omics or functional precision oncology, are recruiting patients with your histology.

Join the Appendicure Patient Data Registry

A registry captures things mutation panels do not. It captures patient-reported outcomes, treatment timelines, symptom patterns, surveillance schedules, and the lived course of disease over time. For a rare cancer like signet ring appendix cancer, where no single institution sees enough patients to draw firm conclusions on its own, that kind of data is essential. The Appendicure Patient Data Registry is open to anyone with a confirmed appendix cancer diagnosis or their caregivers. It takes time to complete, and it matters.

Get connected to research-active centers

A handful of centers in the United States have built appendix cancer programs that combine clinical care with active research. Even if you receive your treatment locally, a consultation at one of these centers can change the questions being asked about your case. Dr. Patrick Wagner at Allegheny Health Network runs a program with deep experience across appendiceal histologies. Dr. Andrew Lowy at UC San Diego sits on the Appendicure advisory board and leads a long-running research effort on peritoneal surface malignancy. Dr. Edward Levine at Atrium Health Wake Forest Baptist is one of the most experienced surgeons in the field and a trusted figure in the patient community. Dr. George Chang at MD Anderson is a colorectal surgical oncologist whose work includes appendiceal cancers. Dr. Kiran Turaga at Yale is leading the trial mentioned above. These are not the only centers worth knowing about, but they are a strong starting point for anyone trying to figure out where to plug in.

Engage with the broader advocacy community

No single nonprofit can fund every piece of the research that signet ring patients need. The ACPMP Research Foundation and PMP Pals have been part of this community for years, alongside Appendicure, and each plays a different role across research funding, patient connection, and education. The more patients and caregivers who are visible across these organizations, the more weight the appendix cancer community carries when it shows up in consensus guideline development, at the FDA, and in front of researchers deciding where to spend their next grant cycle.

Where the Field Is Organizing

A decade ago, an appendix cancer patient looking for a clinical trial built specifically for their histology would have found close to nothing. That is changing. The Zheng-Pywell AACR GENIE study is one example of multi-institutional collaboration that simply did not exist before. The Mini-Galaxy Model and frameworks like it are examples of computational research now turning toward rare cancers because the tools have finally caught up to the question. The 2025 Peritoneal Surface Malignancies Consortium consensus guidelines, often referred to as the Godfrey guidelines after their first author, were developed by 138 appendiceal cancer specialists through a modified Delphi process and represent the current evidence-based reference for appendiceal cancer management. They represent one of the first comprehensive appendiceal-specific consensus frameworks, instead of borrowing primarily from colorectal cancer research, which is a meaningful shift for a disease that was treated as a footnote to colorectal cancer for decades. A trial like NCT07291180 represents the kind of biology-first research that goes beyond mutation panels alone, an approach many researchers and patients hope will help address unanswered questions in aggressive appendiceal cancers.

None of this is the same as a cure, and signet ring appendix cancer research is still well behind where it should be given how aggressive this histology is. But the direction and the framing have both shifted. The question is no longer only what single mutation can we target, but also what system is producing this disease, and how do we map enough of it to actually intervene.

Closing the Series

Part 1 of this series covered what the published evidence says about treating signet ring appendix cancer. Part 2 covered what your pathology report actually says and why specific details matter for your care. Part 3 has covered why the picture is still incomplete, the research framework that may help complete it, and the concrete steps signet ring patients and caregivers can take to be part of that work.

There is something in all of this that signet ring patients have already known. You have watched identical-looking diagnoses lead to wildly different outcomes. You have been told that nothing on your panel is actionable while your disease has clearly been driven by something. You have lived the trial-and-error quality of care that comes from treating a complex system as if it were a simple one. The research is starting to catch up to what you already felt. The faster patients show up in the registries, the tissue banks, and the trials, the faster that catch-up will happen.

Read the rest of the series:
Part 1: What the Evidence Says About Treatment
Part 2: What Your Pathology Report Actually Says

Related coverage:
What 916 Tumors Are Telling Us About Treating Appendix Cancer

If you would like to be part of the data that drives better signet ring appendix cancer research, you can join the Appendicure Patient Data Registry.

---

Sources and further reading:

Correia C, et al. Mini-Galaxy: Rethinking Complex Human Diseases Through the Lens of Systems Biology and Multilayered AI Network Perspectives. International Journal of Molecular Sciences, 2026. doi:10.3390/ijms27073161

Godfrey EL, et al; Peritoneal Surface Malignancies Consortium Group. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement. Cancer, 2025. doi:10.1002/cncr.35867

Godfrey EL, et al; Peritoneal Surface Malignancies Consortium Group. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors With Peritoneal Involvement. Cancer, 2025. doi:10.1002/cncr.35874

Zheng-Pywell R, et al. Comprehensive Genomic Profiling of Appendiceal Neoplasms: An AACR Project GENIE Study. Annals of Surgical Oncology, 2026.

ClinicalTrials.gov. NCT07291180. https://clinicaltrials.gov/study/NCT07291180

ACPMP Research Foundation. https://acpmp.org

PMP Pals Network. https://pmppals.net

Appendicure does not provide medical advice. Always discuss treatment decisions with your oncology team.